PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy

Zacks12-04

Shares of PTC Therapeutics PTCT rose nearly 19% on Monday after announcing that it has entered into an exclusive global licensing and collaboration agreement with pharma giant Novartis NVS for PTC518,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2488507978?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","is_english":true,"pubTime":"2024-12-04 02:36","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2488507978","market":"us","top_or_hot":-1,"title":"PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy","media":"Zacks","content":"<div>\n<p>Shares of PTC Therapeutics PTCT rose nearly 19% on Monday after announcing that it has entered into an exclusive global licensing and collaboration agreement with pharma giant Novartis NVS for PTC518,...</p>\n\n<a href=\"https://finance.yahoo.com/news/ptct-stock-soars-licensing-deal-183600668.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-04 02:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ptct-stock-soars-licensing-deal-183600668.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of PTC Therapeutics PTCT rose nearly 19% on Monday after announcing that it has entered into an exclusive global licensing and collaboration agreement with pharma giant Novartis NVS for PTC518,...</p>\n\n<a href=\"https://finance.yahoo.com/news/ptct-stock-soars-licensing-deal-183600668.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0079474960.USD","symbol_name":"联博美国增长基金A","start_time":0,"source_url":"https://finance.yahoo.com/news/ptct-stock-soars-licensing-deal-183600668.html","article_id":"2488507978","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488507978","pubTimestamp":1733250960,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Shares of PTC Therapeutics PTCT rose nearly 19% on Monday after announcing that it has entered into an exclusive global licensing and collaboration agreement with pharma giant Novartis NVS for PTC518, its investigational oral therapy for Huntington's disease .Per the terms of the deal, Novartis will be responsible for developing and marketing PTC518 in HD indication after completion of the ongoing phase II PIVOT-HD study, expected in the first half of next year. PTC Therapeutics will receive an upfront cash payment of $1 billion. The company will also be eligible to receive up to $1.9 billion in milestone payments from Novartis.While both companies will share profits and losses in the United States in the ratio of 40:60 , NVS will be responsible for ex-U.S. sales. PTCT will also be eligible to receive tiered double-digit royalties on ex-U.S. sales of the drug.The deal is expected to be closed in first-quarter 2025, subject to the fulfillment of customary closing conditions, including r","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0079474960.USD":"联博美国增长基金A","BK4566":"资本集团","CSTL":"Castle Biosciences, Inc.","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4196":"保健护理服务","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","BK4121":"生命科学工具和服务","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4550":"红杉资本持仓","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","BK4083":"家庭装潢零售","LU2756315664.SGD":"ALLIANZ INCOME AND GROWTH \"AMI\" (SGDHDG) INC","PTCT":"PTC Therapeutics Inc.","SPRO":"Spero Therapeutics Inc.","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","BK4581":"高盛持仓","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","CRL":"查尔斯河","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","BK4530":"医药外包概念","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","NVS":"诺华","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","BK4534":"瑞士信贷持仓","HD":"家得宝","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC"},"translate_title":"PTCT股价因与NVS达成亨廷顿舞蹈症疗法许可协议而飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRO":1,"PTCT":1,"NVS":1,"HD":1,"CSTL":1,"CRL":1},"content_text":"Shares of PTC Therapeutics PTCT rose nearly 19% on Monday after announcing that it has entered into an exclusive global licensing and collaboration agreement with pharma giant Novartis NVS for PTC518, its investigational oral therapy for Huntington's disease (HD).\nPer the terms of the deal, Novartis will be responsible for developing and marketing PTC518 in HD indication after completion of the ongoing phase II PIVOT-HD study, expected in the first half of next year. PTC Therapeutics will receive an upfront cash payment of $1 billion. The company will also be eligible to receive up to $1.9 billion in milestone payments from Novartis.\nWhile both companies will share profits and losses in the United States in the ratio of 40:60 (40% PTC and 60% Novartis), NVS will be responsible for ex-U.S. sales. PTCT will also be eligible to receive tiered double-digit royalties on ex-U.S. sales of the drug.\nThe deal is expected to be closed in first-quarter 2025, subject to the fulfillment of customary closing conditions, including regulatory approvals.\nPTCT Stock’s Performance\nWall Street was impressed with the licensing deal. If the deal is successfully closed, management plans to use the proceeds to expand its drug development platform and strengthen its commercial activities.\nSome investors also opined that the deal further validates PTC’s HD drug. In June, PTC reported interim data from the PIVOT-HD study, which showed that treatment with PTC518 resulted in a durable, dose-dependent reduction of huntingtin protein in the blood and the fluid surrounding the brain and spine.\nYear to date, PTC Therapeutics’ shares have soared 88.9% against the industry’s 5.2% decline.\nImage Source: Zacks Investment Research\nRecent Developments in PTCT Stock\nThe Novartis deal is one of the few positive boosts to PTC Therapeutics stock this year. Last month, the FDA granted accelerated approval to the company’s gene therapy Kebilidi for treating AADC deficiency. This marks the approval for the first gene therapy in the United States that is directly administered to the brain.\nIn October, management resubmitted the regulatory filing seeking approval for Translarna in nonsense mutation Duchenne muscular dystrophy (nmDMD). Since a previous filing on the drug was issued a complete response letter (CRL) in 2016, the FDA is not obliged to provide a target action date, though it accepted the company’s resubmission.\nIn July, PTC filed a regulatory filing seeking approval with the FDA for sepiapterin to treat phenylketonuria (PKU) in pediatric and adult patients. A final decision is expected by July 29, 2025.\nHowever, the company has also suffered some setbacks. Last week, management reported that a mid-stage study evaluating its investigational ALS drug utreloxastat did not meet the primary and secondary endpoints.\nPTCT’s Zacks Rank\nPTC Therapeutics currently carries a Zacks Rank #3 (Hold).\n\nPTC Therapeutics, Inc. Price\n\nPTC Therapeutics, Inc. price | PTC Therapeutics, Inc. Quote\n\nKey Picks Among Biotech Stocks\nA couple of better-ranked stocks from the sector are Castle Biosciences CSTL and Spero Therapeutics SPRO, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for Castle Biosciences’ 2024 loss per share have narrowed from 58 cents to 8 cents. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.13 to $1.88. Year to date, shares of Castle Biosciences have surged 45.5%.\nCSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.\nIn the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.13. Estimates for 2025 loss per share have narrowed from $1.54 to 54 cents. Year to date, shares of Spero Therapeutics have lost 23.1%.\nSpero Therapeutics’ earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 94.42%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nNovartis AG (NVS) : Free Stock Analysis Report\nPTC Therapeutics, Inc. (PTCT) : Free Stock Analysis Report\nSpero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report\nCastle Biosciences, Inc. (CSTL) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488507978"}